|
業務類別
|
Biotechnology |
|
業務概覽
|
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the bindingof oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). |
| 公司地址
| 2500 Westchester Avenue, Purchase, NY, USA, 10577 |
| 電話號碼
| +1 412 481-2210 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cogrx.com |
| 員工數量
| 14 |
| Dr. Anthony Caggiano, M.D.,PhD |
Chief Medical Officer and Head, Research and Development |
美元 503.01K |
27/04/2026 |
| Ms. Lisa Ricciardi |
Director, Chief Executive Officer and President |
美元 651.02K |
27/04/2026 |
| Mr. John Doyle |
Chief Financial Officer and Principal Accounting Officer |
美元 460.58K |
27/04/2026 |
|
|
| Ms. Peggy Wallace |
Independent Director |
27/04/2026 |
| Dr. Aaron G.L. Fletcher, PhD |
Independent Director |
27/04/2026 |
| Dr. Brett P. Monia, PhD |
Independent Director |
27/04/2026 |
| Mr. Jack A. Khattar |
Chairman of the Board |
27/04/2026 |
| Ms. Lisa Ricciardi |
Director, Chief Executive Officer and President |
27/04/2026 |
| Ms. Ellen B. Richstone |
Independent Director |
27/04/2026 |
|
|
|
|
